A randomized phase II study comparing single-agent docetaxel to alternating docetaxel-gemcitabine as primary chemotherapy in patients with metastatic breast cancer.

Trial Profile

A randomized phase II study comparing single-agent docetaxel to alternating docetaxel-gemcitabine as primary chemotherapy in patients with metastatic breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 03 Jun 2008 Final results reported at ASCO 2008.
    • 26 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 10 Nov 2007 Status change from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top